Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Studies in rodents have implicated various cytokines as paracrine mediators of increased osteoclastogenesis during estrogen deficiency, but increases in RANKL, the final effector of osteoclastogenesis, have not been demonstrated. Thus, we isolated bone marrow mononuclear cells expressing RANKL on their surfaces by two-color flow cytometry using FITC-conjugated osteoprotegerin-Fc (OPG-Fc-FITC) as a probe. The cells were characterized as preosteoblastic marrow stromal cells (MSCs), T lymphocytes, or B lymphocytes by using Ab's against bone alkaline phosphatase (BAP), CD3, and CD20, respectively, in 12 premenopausal women (Group A), 12 early postmenopausal women (Group B), and 12 age-matched, estrogen-treated postmenopausal women (Group C). Fluorescence intensity of OPG-Fc-FITC, an index of the surface concentration of RANKL per cell, was increased in Group B over Groups A and C by two- to threefold for MSCs, T cells, B cells, and total RANKL-expressing cells. Moreover, in the merged groups, RANKL expression per cell correlated directly with the bone resorption markers, serum C-terminal telopeptide of type I collagen and urine N-telopeptide of type I collagen, in all three cell types and inversely with serum 17beta-estradiol for total RANKL-expressing cells. The data suggest that upregulation of RANKL on bone marrow cells is an important determinant of increased bone resorption induced by estrogen deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, estrogen deficiency is associated with an expansion of RANKL-and TNF-expressing T cells and B cells (27,28,30,31).”
From Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics (2016) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“RANKL levels were increased on the surface of bone marrow cells from early postmenopausal women who are estrogen deficient”
From Pathogenesis of osteoporosis: concepts, conflicts, and prospects (2005) · cites this paper as [48]
In the citing paper
“Moreover, estrogen stimulates these bone cells to produce osteoprotegerin (OPG), a decoy receptor of RANK in osteoclast, thus inhibiting osteoclastogenesis [19, 155–159].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [157]
In the citing paper
“In humans, estrogen deficiency is associated with increased RANKL expression by bone marrow osteoblastic, T and B cells, whereas estrogen treatment reversed this increase ( 76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
In the citing paper
“flow cytometry studies conducted with bone marrow aspirates from postmenopausal subjects showed that saturating levels of OPG did not reduce the ability of anti-TRAIL antibodies to recognize TRAIL-positive cells (76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“The expression of RANKL by T cells may be related, in part, to their function as immunoregulators, because targeted disruption of the RANKL gene results in mice lacking lymph nodes and with defective T and B lymphocyte differentiation (45).”
BackgroundSelf-citationManolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471 · cited 1×
“For example, ERα knockout mice have short limbs and mild osteopenia (31), whereas a young adult male with homozygous null mutations of ERα had elongated limbs and a greater degree of osteopenia (32).”
BackgroundSuda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,336
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856 · cited 1×
“In an experimental mouse model of inflammatory arthritis, activated T lymphocytes expressing RANKL were shown to regulate the associated periarticular bone loss and joint destruction (46).”
BackgroundSelf-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Self-citation
Research works printed but not linked: 8
- 10.1210/jc.87.4.1443 · doi:10.1210/jc.87.4.1443 · Paper page
- 10.1210/en.142.12.5050 · doi:10.1210/en.142.12.5050 · Paper page
- 10.1210/en.140.9.4367 · doi:10.1210/en.140.9.4367 · Paper page
- 10.1210/en.142.6.2205 · doi:10.1210/en.142.6.2205 · Paper page
- 10.1210/jc.87.4.1550 · doi:10.1210/jc.87.4.1550 · Paper page
- 10.1210/en.141.12.4768 · doi:10.1210/en.141.12.4768 · Paper page
- Owen, 1988, Ciba Found. Symp., 136, 42
- 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6 · DOI
Cited by
Items 601–700 of 821
EFFECT OF BLACK COHOSH ON BIOCHEMICAL MARKERS OF BONE REMODELING IN POSTMENOPAUSAL WOMEN
Carlisle, A. P., Jessup, J., Simpson, S. H., & Yoon, S. L. (2009) · Journal of Midwifery & Women s Health · doi:10.1016/j.jmwh.2009.06.013 · Cited by 6
Osteoporosis: Diagnosis and Management
Ward, L. M., & Ma, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-73782-9_24 · Cited by 6
Wawrzyniak, A., Skrzypczak-Zielińska, M., Krela‐Kaźmierczak, I., Michalak, M., Marszalek, D., Marcinkowska, M., Zakerska‐Banaszak, O., & Słomski, R. (2020) · Advances in Medical Sciences · doi:10.1016/j.advms.2020.05.001 · Cited by 5
Callus formation in albino Wistar rats after femur fracture assessed by visible spectroscopy
Orban, E., Pap, Z., Micu, A. M., Şipoş, R. S., & Fechete, R. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.09.114 · Cited by 7
Of mice and men: pathophysiology of male osteoporosis
Patsch, J., Muschitz, C., Resch, H., & Pietschmann, P. (2007) · The Journal of Men s Health and Gender · doi:10.1016/j.jmhg.2006.05.010 · Cited by 6
“RANKL-expression on marrow stromal cells (MSCs) is upregulated two-to threefold by estrogen deficiency and directly correlates with increases in bone resorption markers [22].”
In Vitro Findings of Titanium Functionalized with Estradiol via Polydopamine Adlayer
Steffi, C., Shi, Z., Kong, C. H., & Wang, W. (2017) · Journal of Functional Biomaterials · doi:10.3390/jfb8040045 · Cited by 5
“At cellular level, estradiol inhibits osteoclast differentiation either directly inhibiting osteoclast activity [4] or indirectly, by modulating the gene expression of osteoblasts, T and B cells [5,6].”
BackgroundThomsen, L. K., Christiansen, P. V. D., Andreasen, C. M., & Andersen, T. L. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07612-z · Cited by 4
“The menopausal-induced reduction in estrogen may initially promote an increased osteoclastogenesis by increasing RANKL-expression in osteoblast-lineage cells and osteo-cytes [40, 87, 88].”
Estradiol regulates osteoclast sialylation via ST3Gal1 in postmenopausal osteoporosis
Dou, C., Dan, Y., Zhang, Z., Li, X., Qu, Y., Wu, Y., Zhang, Z., Guo, S., Xu, J., & Luo, F. (2026) · Bone Research · doi:10.1038/s41413-025-00498-x · Cited by 7
“10,11 In fl ammatory cytokines such as TNF, IL-1, and IL-6, secreted by mesenchymal stem cells (MSCs) and lymphocytes, further promote osteoclastogenesis.”
Yan, S., Du, Q., Zhao, L., Liu, Q., Wu, M., Xu, Z., & Shen, J. (2026) · Chinese Medicine · doi:10.1186/s13020-026-01353-9 · Cited by 7
“Pro-inflammatory cytokines, including TNF-α, interleukin-1 (IL-1β), and interleukin-6 (IL-6), directly modulate bone cell activity by enhancing osteoclast differentiation while suppressing osteoblast function— effects that occur independently of RANKL signaling at the preosteoclast level [100].”
Lan, Y., Peng, Q., Shen, J., & Liu, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-78707-6 · Cited by 4
“Heightened expression of the Receptor Activator of Nuclear Factor κ-B Ligand (RANKL) in postmenopausal women significantly contributes to the pathogenesis of OP 52 .”
Integrative analysis of genetic and clinical risk factors for bone loss in a Korean population
Lee, J. H., Park, J., Kim, J. H., Choi, J., Choi, H. J., Ku, E. J., Hong, A. R., Shin, C. S., & Cho, N. H. (2021) · Bone · doi:10.1016/j.bone.2021.115910 · Cited by 4
Is there a role for essential fatty acids in osteoporosis?
Das, U. N. (2024) · European Journal of Clinical Nutrition · doi:10.1038/s41430-024-01456-2 · Cited by 4
“PGE2, IL-1, IL-11, TNF-α , and glucocorticoids induce RANKL expression in osteoblasts that may account for their pro-osteoporotic action [48].”
Oral Infections and Autoimmune Diseases
Janket, S., Kanasi, E., & Baird, A. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-63269-2.00063-5 · Cited by 4
The Basic Biology of Estrogen and Bone
Almeida, M. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-459-9_14 · Cited by 5
Lee, G. C., Kim, B., Ko, Y., Park, M., Kim, D., Ryu, K. H., Jun, Y. C., Sohn, H. M., & Lim, W. (2017) · Photomedicine and Laser Surgery · doi:10.1089/pho.2016.4134 · Cited by 5
Kim, C.-S., Kim, H., Kim, J.-Y., Kim, J., Park, D., Lim, S.-T., & Min, S. (2017) · Exercise Science · doi:10.15857/ksep.2017.26.1.87 · Cited by 5
“예를 들어, 에스트로겐이 부족한 초기의 폐경 후 여성을 대상으로 조사한 결과, RANKL의 증가가 골흡수를 촉진시키고 있는 것이 보고되고 있 다[38].”
Chapurlat, R. D., & Genant, H. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00069-x · Cited by 7
The Role of the Immune System in the Development of Osteoporosis
Mödder, U. I., Riggs, B. L., & Khosla, S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375670-1.10009-3 · Cited by 4
Self-citationRen, Y., Han, S., & Li, P. (2012) · Chinese Journal of Cancer Research · doi:10.1007/s11670-012-0151-6 · Cited by 4
“Inhibition effect of estrogen on oesteoclasts is associated with OPG and RANKL[28-30].”
BackgroundEstrogen and the death of osteoclasts: A fascinating story
Khosla, S. (2007) · BoneKEy-Osteovision · doi:10.1138/20070275 · Cited by 4
“Finally, as shown in Figure 1C, estrogen deficiency upregulates osteoblastogenesis (19) and expands the numbers of T-cells (20); both osteoblastic and T-cells produce RANKL (21), which leads to enhanced osteoclast development.”
BackgroundSelf-citationMatsuyama, Y., Sakuma, Y., Suzuki, M., Orita, S., Yamauchi, K., Inoue, G., Aoki, Y., Ishikawa, T., Miyagi, M., Kamoda, H., et al. (2014) · Asian Spine Journal · doi:10.4184/asj.2014.8.5.557 · Cited by 4
“In several inflammatory diseases, such as menopausal osteoporosis, rheumatoid arthritis, and periodontitis, there is increased production of the proinflammatory cytokines TNF-α, NF-kB, and RANKL, and these factors play a crucial role in the disease [12-17].”
BackgroundOsteoimmunological Insight in to Vertebral Fractures in Osteoporosis
Saghafi, H., Hossein‐Nezhad, A., Sedighi, N., Tofighi, P., Soltani, A., Larijani, B. A., & Hafezi, R. (2008) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 4
Laboratory Assessment of Postmenopausal Osteoporosis
Garnero, P., & Delmas, P. D. (2006) · Elsevier eBooks · doi:10.1016/b9-78-012088-5/62650-0388 · Cited by 4
Basic Principles of Bone Cell Biology
Martin, T. J., Ng, K. W., & Sims, N. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-415784-2.00002-6 · Cited by 11
Billington, E. O., & Reid, I. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64552-x · Cited by 5
Manolagas, S. C., Almeida, M., & Jilka, R. L. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch25 · Cited by 9
Membrane-bound or soluble, mesenchymal or myeloid: which RANKL drives osteoclastogenesis?
Zhang, T., Feng, Y., Wang, W., Wang, W., Shan, L., Yang, X., Sun, H., & Feng, S. (2026) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2025.146 · Cited by 7
Li, J., Fan, J., Yao, Z., Jiao, H., Duan, R., Sanders, J. O., Mesfin, A., Xing, L., & Boyce, B. F. (2026) · Bone Research · doi:10.1038/s41413-026-00525-5 · Cited by 5
“It is likely that during aging, increasing amounts of CXCL12 are produced by multiple cell types in BM, thereby attracting RCBs; 3) CD138 is a marker of plasma cells.”
InfluentialFeng, Y., Wang, H., Xu, S., Huang, J., Pei, Q., & Wang, Z. (2023) · Bone · doi:10.1016/j.bone.2023.116990 · Cited by 3
Ke, D., Gao, T., Dai, H., Xu, J., & Ke, T. (2025) · Differentiation · doi:10.1016/j.diff.2025.100863 · Cited by 3
Nouvelles cibles thérapeutiques dans l’ostéoporose
Roux, S. (2010) · Revue du Rhumatisme · doi:10.1016/j.rhum.2009.10.032 · Cited by 5
Dalezis, P., Trafalis, D. T., Geromichalos, G. D., Pissimissis, N., Panagiotopoulou, D., Galaktidou, G., Papageorgiou, E., Papageorgiou, A., Lymperi, M., & Koutsilieris, M. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000484 · Cited by 4
Bone Density and Imaging of Osteoporosis
Chapurlat, R. D., Delmas, P. D., & Genant, H. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00068-x · Cited by 3
Osteoporosis: Pathophysiology and Clinical Aspects
Mikosch, P. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0520-7_7 · Cited by 5
Der RANK-Ligand-Antikörper Denosumab als Beispiel der biotechnologischen Medikamentenentwicklung
Trubrich, A., Kocijan, R., Muschitz, C., & Resch, H. (2011) · Osteologie/Osteology · doi:10.1055/s-0037-1619994 · Cited by 3
“Beispielsweise konnten Eghbali-Fatourechi und Mitarbeiter eine erhöhte RANKL- Expression bei Knochenmarkszellen postmenopausaler gegenüber prämenopausalen Frauen nachweisen (15).”
BackgroundGuo, Y., Li, M., Zhusheng, L., Yamada, T., Sasaki, M., Hasegawa, T., Hongo, H., Tabata, C., Suzuki, R., Oda, K., et al. (2012) · Journal of Electron Microscopy · doi:10.1093/jmicro/dfs052 · Cited by 3
“B (RANK) and RANK ligand (RANKL), as previously reported [24-26].”
MethodRosenzweig, A. B., & Pignolo, R. J. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-467-8_1 · Cited by 3
Regulatory Mechanisms of Bone Development and Function
El-Ganzuri, M., Ahmed, R., & Bastawy, E. M. (2016) · Annals of Cytology and Pathology · doi:10.17352/acp.000002 · Cited by 6
“Monocytes, T cells and B cells from individuals with postmenopausal osteoporosis have a higher density of RANKL on their cell membrane [138], and oestrogen can positively regulate OPG expression [139].”
BackgroundLindsay, R., & Cosman, F. (2007) · Elsevier eBooks · doi:10.1016/b978-012369443-0/50032-6 · Cited by 3
Postmenopausal Osteoporosis: How the Hormonal Changes of Menopause Cause Bone Loss
Pacifici, R. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50043-4 · Cited by 7
Kang, N. (2012) · TSpace (University of Toronto) · Cited by 5
A novel effect of geraniin on OPG/RANKL signaling in osteoblasts
Zhang, X., Yang, R., Long, J., He, B., Zhang, Y., Fu, T., Shen, Z., & Chen, P. (2018) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902018000317567 · Cited by 2
Chitosan based bionanocomposites in osteoporosis
Niranjan, M. K., Baghel, K., & Azam, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821280-6.00014-3 · Cited by 2
Nasulewicz‐Goldeman, A., Goldeman, W., Nikodem, A., Nowak, M., Papiernik, D., Goszczyński, T. M., & Wietrzyk, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179590 · Cited by 2
“Then, BMDMs were cultured in the presence of RANKL and M-CSF and either WG12399C, WG12592A, or reference zoledronate.”
BackgroundInfluentialRauner, M., & Hofbauer, L. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-34238-2_1 · Cited by 4
On the evolution and contemporary roles of bone remodeling
Kostenuik, P. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00031-9 · Cited by 4
Mettwally, W. S. A., Hussein, R. A., Jaleel, G. A. A., Hassan, A. H. M., Saleh, D. O., & El‐Beih, A. A. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.106226 · Cited by 2
Singh, M., Sabharwal, S., Jamwal, N., Gupta, M., & Garg, K. (2025) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_108_25 · Cited by 2
“[7] The antiresorptive therapies currently utilized to prevent or treat metabolic bone diseases work by altering the expression of RANKL/OPG.”
Dougall, W. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00032-3 · Cited by 3
Influencing the Effect of Treatment of Diseases Related to Bone Remodelling by Dynamic Loading
Klika, V., Mark, F., & Mak, I. (2010) · InTech eBooks · doi:10.5772/7082 · Cited by 3
Pathophysiology and Aging of Bone
Pietschmann, P., Gruber, R., & Peterlik, M. (2008) · Medical radiology · doi:10.1007/978-3-540-68604-0_2 · Cited by 3
Skeletal Health in Pediatric Inflammatory Bowel Disease
Sylvester, F. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-73481-1_11 · Cited by 3
“RANKL has been implicated as a key factor in the pathogenesis of bone loss associated with increased resorption, like in post-menopausal osteoporosis [18] and inflammation [19].”
BackgroundRANKL/OPG in Breast Cancer — Extending Its Territory to BRCA Mutation Carriers
Rachner, T. D., & Rauner, M. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.09.035 · Cited by 2
“This may be especially true for RANKL, where previous studies reported elevated levels of RANKL in the cells of the bone microenvironment in postmenopausal women, and while this increase was reversed in women receiving hormone replacement therapy in bone cells, no changes in serum RANKL were observed between the group…”
BackgroundResultInfluentialKASE, N. G. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003254.021 · Cited by 2
Böcker, W., Radic, T., Schönitzer, V., Haasters, F., Mutschler, W., & Schieker, M. (2011) · Gene · doi:10.1016/j.gene.2011.08.008 · Cited by 2
Nuclear Receptor Regulation of Osteoclast and Bone Remodeling
Jin, Z., Li, X., & Wan, Y. (2015) · Cited by 2
IMMUNOPATHOGENETIC MECHANISMS OF PERIODONTAL DISEASE AND POSTMENOPAUSAL OSTEOPOROSIS
Đorđević, N. S., Medarov, M., Kostić, M. S., Petrović, M. S., Cekić, S., & Ajduković, Z. (2012) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 2
Clinical Disorders Associated with Alterations in Bone Resorption
Rubin, J. E., & Nanes, M. S. (2005) · Springer eBooks · doi:10.1007/1-84628-016-8_7 · Cited by 2
“Estrogen deficiency is associated with increased RANKL expression by both stromal cells and circulating T cells [26].”
BackgroundIntercellular Communication during Bone Remodeling
Martin, T. J., & Rodan, G. A. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50022-7 · Cited by 6
The Role of Sex Steroids in the Effects of Immune System on Bone
Grčević, D., Kovačić, N., & Lee, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800571-2.00012-8 · Cited by 2
Fast, D., Chandra, A., Lin, Y., Murray, M., & Gellenbeck, K. W. (2012) · CRC Press eBooks · doi:10.1201/b12893-6 · Cited by 2
Clinical and epidemiological studies: skeletal changes across menopause
Cauley, J. A., & Greendale, G. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00024-1 · Cited by 2
Idiopathic Condylar Resorption
Posnick, J. C. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2698-1.00036-8 · Cited by 2
Labah, D. A. (2017) · Egyptian Dental Journal /Egyptian Dental Journal · doi:10.21608/edj.2017.76056 · Cited by 3
Endocrinology of Bone and Growth Disorders
Farquharson, C., Stephen, L. A., & Wong, S. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00086-4 · Cited by 3
Intercellular Communication during Bone Remodeling
Martin, T. J., & Rodan, G. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375098-3.50021-4 · Cited by 3
Upmanyu, V., Sapra, L., & Srivastava, R. K. (2022) · Studies in natural products chemistry · doi:10.1016/b978-0-323-91250-1.00005-7 · Cited by 2
Osteoimmunology: The Bone-Immune Crosstalk
Chiappelli, F. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9495-0_1 · Cited by 3
Kerschan‐Schindl, K., Nebot, E., & Pietschmann, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-64597-1_153-1 · Cited by 2
Biological characteristics of osteoporosis drugs: the effect of osteoblast–osteoclast coupling
Kim, S., Moon, S. J., & Seo, J. T. (2019) · International Journal of Oral Biology · doi:10.11620/ijob.2019.44.1.1 · Cited by 2
“Besides the direct effects, estrogen decreases production of RANKL and increases production of osteoprotegrin, a decoy receptor for RANKL, by osteoblasts [24,25].”
BackgroundOsteoporosis in men: what is similar and what is different?
Laurent, M. R., Gielen, E., ORWOLL, E. S., & Vanderschueren, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00025-3 · Cited by 4
Looking for answers in all the wrong places*
McClung, M. R. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31802d0481 · Cited by 2
Pacifici, R., & Weitzmann, M. N. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch128 · Cited by 2
Mechanisms of Osteoprotective Actions of Estrogens
Kato, S., Sawatsubashi, S., Yokoyama, A., Nakamura, T., & Kouzmenko, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11273-5 · Cited by 3
Die Rolle von RANK-Ligand und Osteoprotegerin bei Osteoporose
Hofbauer, L. C. (2004) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 4
The role of vitamin D and physical activity on osteopenia and osteoporosis
Holubiac, I. Ș. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85174-9.00019-4 · Cited by 1
GalNAc ‐Conjugated siRNA Targeting Complement C3 Inhibits Osteoclast Activation in Periodontitis
Chen, Y., Liu, Y., Fu, Z.-G., Xu, J., Guo, L., Cao, H., Gan, L., Gao, S., & Liu, Y. F. (2024) · Oral Diseases · doi:10.1111/odi.15170 · Cited by 1
RANK IVVY motif plays crucial roles in osteoclastogenesis
Chen, S., Shi, Z., Jules, J., Li, Y., Kesterson, R. A., Elbahoty, M. H., Zhang, P., & Feng, X. (2024) · Bone · doi:10.1016/j.bone.2024.117367 · Cited by 1
Non-pyroptotic caspase-11 activity regulates osteoclastogenesis and pathological bone loss
Piao, X., Song, J. H., Kim, J.-W., Kwon, S., Oh, S., Sharma, S., Park, S., Wang, Z., Fang, Z., Ryu, J., et al. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01596-3 · Cited by 5
Natural Products in Age-Related Osteoporosis: Mechanisms, Health Benefits, and Food Processing
Yu, X., Shen, M., Ma, J., Sun, K., Li, Y., Xiong, W., & Zhang, Q. (2025) · Food Reviews International · doi:10.1080/87559129.2025.2609584 · Cited by 2
“[37,38] In osteoblasts, estrogen activates the Src/Shc/ERK signaling cascade and suppresses JNK activity, thereby modulating the activity of transcription factors including Elk-1, CCAAT enhancer-binding protein β (C/EBPβ), CREB, and c-Jun/c-Fos.”
Liu, S., Yang, Q., Liu, H., He, Z., Tang, X., Yang, Y., Lin, Y., & Luo, E. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.175445 · Cited by 4
Lamarca, M. (2012) · InTech eBooks · doi:10.5772/30164 · Cited by 1
“Thus, the presence of estrogen prevents binding of RANK-L to RANK resulting in inhibition of the formation, differentiation and survival of osteoclasts (Eghbali-Fatourechi et al., 2003).”
BackgroundMohsen, M. A., Afifi, A. A., & Al-Bagoury, I. (2011) · International Journal of Osteoporosis and Metabolic Disorders · doi:10.3923/ijom.2012.13.24 · Cited by 1
Das, M., Biswas, U. K., & Kumar, A. (2015) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v6i4.11853 · Cited by 1
Rishika, J., Vijayalakshmi, V., Rajanna, A., Naresh, V., & Challa, S. (2016) · Vitamins & Minerals · doi:10.4172/2376-1318.1000146 · Cited by 2
“To conclude, possible mechanism involving the synergistic effects of Cowpea isoflavones and Vitamin D in improving bone turnover could be due to enhanced osteoblastic activity by promoting osteoblasts to secrete OPG and its binding to RANKL leading to suppression of the preosteoclast and osteoclast differentiation, th…”
BackgroundChapter 31 – Clinical and Epidemiological Studies: Skeletal Changes across Menopause
Cauley, J. A., Danielson, M. E., & Greendale, G. A. (2013) · Cited by 1
Yunaini, L., Suryandari, D. A., Kusdhany, L. S., Kurniati, M., Reihannisha, I., & Auerkari, E. I. (2018) · OnLine Journal of Biological Sciences · doi:10.3844/ojbsci.2018.358.364 · Cited by 3
Osteoblast biology: developmental origin and interactive nature of osteoblasts
van der Eerden, B. C. J., & van Wijnen, A. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00006-x · Cited by 3
Clinical and Epidemiological Studies
Cauley, J. A., Danielson, M. E., & Greendale, G. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00031-5 · Cited by 1
Martínez‐Reina, J., Calvo-Gallego, J., Gutiérrez-Millán, F., Pivonka, P., & Gresser, G. (2023) · International Conference on Computational Methods for Coupled Problems in Science and Engineering (COUPLED PROBLEMS) · doi:10.23967/c.coupled.2023.019 · Cited by 1
“The OD ocurring after menopause has been reported to produce an enhanced RANKL expression by stromal cells and lymphocytes [11] which was modelled here by a sigmoidal increase or RANKL production P PMORANKL .”
BackgroundIsmael, A. K., & Alabassi, H. M. (2024) · Ibn AL- Haitham Journal For Pure and Applied Science · doi:10.30526/37.1.3367 · Cited by 1
Emerging roles of osteocytes in the regulation of bone and skeletal muscle mass
Moin, M. R., Das, S., & Sanyal, S. (2024) · Journal of Molecular Endocrinology · doi:10.1530/jme-24-0033 · Cited by 1
Estrogen receptor beta is a negative regulator of mammary cell proliferation
Song, X. (2014) · ScholarWorks -A service of University of Vermont Libraries (University of Vermont) · Cited by 1
Evaluation of the height of premenopausal and postmenopausal women in Zaria, Nigeria
Achie, L. N., Olorunshola, K. V., & M. Mabrouk (2014) · Journal of Physiology and Pathophysiology · doi:10.5897/jpap2013.0085 · Cited by 1
Biochemische Marker des Knochenstoffwechsels nach Osteotomie Das Schaf als Osteoporosemodell
der Ludwig-Maximilians-Universität, F., & Rambeck, W. A. (2007) · Cited by 1
Yu, Q. (2016) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
The Molecular Biology of Sex Steroids in Bone
Kousteni, S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374602-3.00022-5 · Cited by 2
Marchini, A. M. P. D. S., Santana-Melo, G. D. F., Salgado, M. C. M., Zutin, E. A. D. L., Marchini, L., da Rocha, R. F., & de Vasconcellos, L. M. R. (2018) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2018.07.006 · Cited by 1
Pathophysiology of Osteoporosis
Ferrari, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-26757-9_1 · Cited by 2
What Are the Mechanisms and Effects of Age-Related Shortening of the Spine?
Weingarten, J. P. (2018) · The Science Journal of the Lander College of Arts and Sciences · Cited by 3
Metadata
- Authors
- Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L.
- Affiliations
- Mayo Clinic (US)
- Amgen (United States) (US)
- Corresponding author
- Riggs, B. Lawrence
- Venue
- Journal of Clinical Investigation
- Published
- 2003-04-15
- Volume
- 111
- Issue
- 8
- Pages
- 1221-1230
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC152939
- OpenAlex
- W4254761345
- Cited by
- 825
- References
- 44
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 28 · 2023: 25 · 2022: 34 · 2021: 36 · 2020: 41 · 2019: 30 · 2018: 39 · 2017: 39 · 2016: 33 · 2015: 45 · 2014: 31 · 2013: 42 · 2012: 52
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- National Institutes of Health (M01-RR00 585, AG 04875, RR-00585)
- U.S. Public Health Service (AG-04875)
- National Institute on Aging (P01-AG04875, P01AG004875)
- National Center for Research Resources (M01-RR00 585, M01RR000585)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- RANK ligand, bone resorption, postmenopausal osteoporosis, estrogen deficiency, osteoclastogenesis, mesenchymal stem cells, T cells, B cells, osteoprotegerin, estradiol, bone turnover markers, paracrine signaling
- MeSH terms
- Adult, Bone Resorption, Carrier Proteins, Female, Flow Cytometry, Glycoproteins, Humans, Membrane Glycoproteins, Middle Aged, Tumor Necrosis Factor-alpha, Osteoporosis, Postmenopausal, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Apoptosis Regulatory Proteins, TNF-Related Apoptosis-Inducing Ligand, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.